



**Supplementary Figure 6.** Comparison of PFS according to the type of drug prescribed in the TKI group. PFS was compared between TARE versus sorafenib (A, B), TARE versus lenvatinib (C, D), and sorafenib versus lenvatinib (E, F) before and after applying IPTW. IPTW, inverse probability of treatment weighting; PFS, progression-free survival; TARE, transarterial radioembolization; TKI, tyrosine kinase inhibitor.